6 hours Ago By Defense World Staff
AnaptysBio ( NASDAQ:ANAB – Get Free Report ) had its price target cut by stock analysts at JPMorgan Chase & Co. from $66.00 to $36.
00 in a report issued on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.
‘s price target points to a potential upside of 147.42% from the stock’s previous close. A number of other brokerages have also issued reports on ANAB.
UBS Group boosted their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th.
BTIG Research lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. Truist Financial decreased their target price on AnaptysBio from $30.00 to $20.
00 and set a “hold” rating on the stock in a research report on Wednesday. HC Wainwright cut AnaptysBio from a “buy” rating to a “neutral” rating and cut their price target for the company from $52.00 to $19.
00 in a report on Wednesday, December 11th. Finally, Wells Fargo & Company decreased their price objective on AnaptysBio from $56.00 to $40.
00 and set an “overweight” rating on the stock in a report on Thursday, December 12th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.
com, AnaptysBio has an average rating of “Moderate Buy” and an average target price of $41.45. Check Out Our Latest Research Report on ANAB AnaptysBio Price Performance AnaptysBio ( NASDAQ:ANAB – Get Free Report ) last announced its earnings results on Tuesday, November 5th.
The biotechnology company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.72) by $0.
58. The firm had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.
92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.
75%. Equities analysts expect that AnaptysBio will post -6.02 EPS for the current fiscal year.
Insider Activity at AnaptysBio In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.
67, for a total transaction of $58,005.00. Following the completion of the transaction, the insider now directly owns 15,398 shares of the company’s stock, valued at approximately $595,440.
66. This trade represents a 8.88 % decrease in their ownership of the stock.
The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link . 33.70% of the stock is owned by insiders.
Institutional Investors Weigh In On AnaptysBio Hedge funds have recently made changes to their positions in the company. Barclays PLC boosted its position in AnaptysBio by 117.4% in the third quarter.
Barclays PLC now owns 44,300 shares of the biotechnology company’s stock valued at $1,486,000 after buying an additional 23,926 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of AnaptysBio by 3.0% in the 3rd quarter.
Geode Capital Management LLC now owns 465,401 shares of the biotechnology company’s stock worth $15,594,000 after acquiring an additional 13,336 shares in the last quarter. Frazier Life Sciences Management L.P.
boosted its holdings in shares of AnaptysBio by 2.0% in the 3rd quarter. Frazier Life Sciences Management L.
P. now owns 2,209,189 shares of the biotechnology company’s stock worth $74,008,000 after acquiring an additional 43,598 shares in the last quarter. XTX Topco Ltd grew its position in AnaptysBio by 49.
1% during the 3rd quarter. XTX Topco Ltd now owns 20,286 shares of the biotechnology company’s stock worth $680,000 after acquiring an additional 6,683 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in AnaptysBio by 4.
8% during the 3rd quarter. Wellington Management Group LLP now owns 65,939 shares of the biotechnology company’s stock valued at $2,209,000 after purchasing an additional 3,048 shares in the last quarter. AnaptysBio Company Profile ( Get Free Report ) AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics.
Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. See Also Five stocks we like better than AnaptysBio What is a Low P/E Ratio and What Does it Tell Investors? Opal Fuels CEO on Steering the Future of Renewable Natural Gas What is a Secondary Public Offering? What Investors Need to Know MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win Overbought Stocks Explained: Should You Trade Them? 2 Underrated Quantum Computing Companies Starting to Rally Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter .
.
